Bioxcel Therapeutics Stock Filter Stocks by Fundamentals
| BTAI Stock | USD 1.37 0.06 4.58% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess BioXcel Therapeutics' long-term financial health and intrinsic value.
BioXcel | Shares Owned by Institutions | Build AI portfolio with BioXcel Stock |
BioXcel Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in BioXcel Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioXcel Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioXcel Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.8 K | Bank Of America Corp | 2025-03-31 | 1.5 K | Group One Trading, Lp | 2025-03-31 | 1.3 K | Sbi Securities Co Ltd | 2025-03-31 | 851 | Federated Hermes Inc | 2025-03-31 | 237 | Allsquare Wealth Management Llc | 2025-03-31 | 175 | Washington Trust Advisors, Inc. | 2025-03-31 | 160 | Tower Research Capital Llc | 2025-03-31 | 152 | Jpmorgan Chase & Co | 2025-03-31 | 116 | Murchinson Ltd. | 2025-03-31 | 136.1 K | Ubs Group Ag | 2025-03-31 | 101.8 K |
BioXcel Fundamentals
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (60.11) % | ||||
| Current Valuation | 83.16 M | ||||
| Shares Outstanding | 6.06 M | ||||
| Shares Owned By Insiders | 9.09 % | ||||
| Shares Owned By Institutions | 11.03 % | ||||
| Number Of Shares Shorted | 352.19 K | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 4.48 X | ||||
| Revenue | 2.27 M | ||||
| Gross Profit | (225 K) | ||||
| EBITDA | (44.16 M) | ||||
| Net Income | (59.6 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 102.95 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | (16.49) X | ||||
| Cash Flow From Operations | (72.03 M) | ||||
| Short Ratio | 0.96 X | ||||
| Earnings Per Share | (11.12) X | ||||
| Price To Earnings To Growth | (0.01) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.043 | ||||
| Market Capitalization | 8.3 M | ||||
| Total Asset | 38.34 M | ||||
| Retained Earnings | (650.2 M) | ||||
| Working Capital | 15.16 M | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
| Net Asset | 38.34 M |
About BioXcel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioXcel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out BioXcel Therapeutics Piotroski F Score and BioXcel Therapeutics Altman Z Score analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.12) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.